jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Pharmacology and PharmacotherapeuticsNOW IN
Article

Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

Rituparna Maiti1★, Jyothirmai Jaida1, P. L. John Israel2, Narendar Koyagura1, Sruthi Mukkisa1★ Corresponding author

  1. 1Anuradha Palani Departments of Pharmacology.
  2. 2General Medicine, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India Research Paper.

CORRESPONDENCE

Rituparna Maiti

Anuradha Palani Departments of Pharmacology.

rituparnamaiti@rediffmail.com

Volume 2, Issue 3 · pp. 150–157 · PUBLISHED 2011 · DOI: 10.4103/0976-500X.83278

View on JPP original site ↗

ABSTRACT

Objective: To compare the effi cacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal refl ux disease (GERD). Materials and Methods: A randomized, single-blinded, outdoor- based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The effi cacy variables were change in GERD symptom scoring, endoscopic fi ndings, and Quality of Life in Refl ux and Dyspepsia (QOLRAD) scoring over 4 weeks. Result: Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were signifi cantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all fi ve domains of the QOLARD questionnaire including overall scoring revealed a statistically signifi cant improvement in the rabeprazole group. Endoscopic fi ndings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no signifi cant difference in the incidence of adverse effects. Conclusion: Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better effi cacy and safety profi le.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Maiti, R., Jaida, J., Israel, P. L. J., Koyagura, N., & Mukkisa, S. (2011). Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. Journal of Pharmacology and Pharmacotherapeutics, 2(3), 150–157. https://doi.org/10.4103/0976-500X.83278